Bioxcel Therapeutics Announces That An Independent Data Safety Monitoring Board Recommended That The Serenity At-Home Pivotal Phase 3 Safety Trial Of BXCL501 For Acute Treatment of Agitation Associated With Bipolar Disorders Or Schizophrenia Continue With